hostile takeover

NEW YORK (GenomeWeb News) – Following notification by a hedge fund headed by Carl Icahn of its intentions to acquire a stake in Hologic, the Bedford, Mass.-based firm today announced it has adopted a stockholder rights plan "intended to ensure that the board remains in the best position to perfor

This article has been updated with comments from an internal Illumina e-mail.
By a GenomeWeb staff reporter

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Roche today reported that its molecular diagnostics sales increased 4 percent year over year, while its sales for microarrays and genomic sequencing products dropped sharply.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Institutional Shareholder Services, a proxy-advisory firm, today recommended that Illumina's shareholders vote against Roche's slate of nominees for Illumina's board of directors.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) — In its pursuit to acquire Illumina in a hostile takeover, Roche has again turned directly to the company's shareholders, aiming to convince them of the attractiveness of its offer.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Illumina has once again rejected Roche's offer to acquire the firm and is urging its shareholders to also reject Roche's slate of nominees for Illumina's board of directors.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Roche said today that is has raised its cash tender offer for Illumina from $44.50 to $51 per share — an increase of 15 percent — valuing the deal at nearly $6.7 billion.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Roche has extended its $5.7 billion hostile takeover bid for Illumina for another month at the same price, the company said today.

Pages

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.